Progression of Dalpiciclib in the treatment of breast cancer
QIN Lili
ZHANG Shaohua
SONG Hua
DONG Xiaopei
LI Fan
Abstract：Currently,breast cancer prevails as the most common malignancy throughout the world.According to Surveillance,Epidemiology,and End Results(SEER)database,hormone receptor-positive(HR+)breast cancer accounts for more than 70%of all breast cancer patients.As well,endocrine therapy is one of the main modalities for the treatment of HR+ advanced breast cancer.Several studies have confirmed that endocrine therapy combined with CDK4/6 inhibitors can significantly improve the prognosis of HR+ advanced breast cancer.Currently CDK4/6 inhibitors including Palbociclib,Abemaciclib,and Ribociclib are applied in clinic.Dalpiciclib is the first CDK4/6 inhibitor independently developed by China,which is a class 1.1 innovative drug.In this article,we review relevant studies of Dalpiciclib in breast cancer,and provide references for Dalpiciclib in the future treatment of breast cancer.
Keywords：Breast cancerDalpiciclibCyclin dependent kinase 4/6(CDK4/6)inhibitorsCurative effect
Publication Date：2024-01-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 90-95 )